WO2010149895A2 - Extrait de graines entieres de moringa sp et son utilisation dans des compositions cosmetiques et/ou dermatologiques - Google Patents
Extrait de graines entieres de moringa sp et son utilisation dans des compositions cosmetiques et/ou dermatologiques Download PDFInfo
- Publication number
- WO2010149895A2 WO2010149895A2 PCT/FR2010/051207 FR2010051207W WO2010149895A2 WO 2010149895 A2 WO2010149895 A2 WO 2010149895A2 FR 2010051207 W FR2010051207 W FR 2010051207W WO 2010149895 A2 WO2010149895 A2 WO 2010149895A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- moringa
- skin
- whole seeds
- seeds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to an extract of whole seeds of Moringa sp. containing oil (including triglycerides, fatty acids and polar lipids) and polyphenols and its use in cosmetic and / or dermatological compositions.
- oil including triglycerides, fatty acids and polar lipids
- polyphenols and its use in cosmetic and / or dermatological compositions.
- Moringa is a tree native to India, but grown all over the world and naturalized in many environments where it is very popular. There are 13 species of Moringa belonging to the family Moringaceae, M. oleifera (synonym: Moringa pterygosperm ⁇ ) being the best known.
- Moringa oleifera is a small tree 4 to 8 meters high, with a clear crown, spread out in parasol.
- the leaves are deciduous 30 to 70 cm long, the flowers are white and very fragrant, the fruit is an elongate capsule linear, trine, leathery and pendulous, reaching 30 to 40 cm long.
- the seeds are globose-trigonal, 1.2 cm long and 1 cm wide, with 3 membranous wings exceeding the seed and 2 cm long.
- Wild or cultivated tree under tropical climate wet or very dry, it can survive in extreme conditions and has a fast growth. Its very deep roots allow it to do without water for several months.
- Ayurvedic medicine to cure 300 diseases in addition to a very important nutritional value.
- the fruits are eaten cooked, the leaves are eaten as a vegetable and have a nutritional value such that they provide a response to malnutrition in some countries.
- a high oleic food oil is derived from seeds that also serve as a flocculant to sanitize water. The oil is obtained by pressure or extraction with hexane seeds freed of their integument. For the use of the flocculant properties, the cake recovered after pressing is used.
- the seeds can be eaten like peas when they are still green. Ripe seeds contain about 40% oil.
- the oil of Moringa sp. is a good quality cooking oil (close to olive oil) also used in perfumery, for the manufacture of soap and as a lamp oil (it is very stable to oxidation).
- the oil is used in application to relieve pain during gout or rheumatism attacks (The Indian Materia Medica, pp. 811- 816). Orally, the seeds are used as antipyretic (Hukkeri et al., Indian J. Pharm Sci (2006) 68, pp 124-126).
- Oil obtained from seeds, obtained by pressing or very apolar extraction is widely used in cosmetics for its nourishing properties due to the triglycerides it contains.
- aqueous extract of seeds in cosmetics is described: the peptides and proteins it contains have anti-wrinkle and purifying properties: the seeds are previously peeled and delipidated (US 6,500,470 patents and US 2006 / 0275247).
- the aqueous and delipidated protein fractions extracted from the whole or shelled seeds of Moringa sp., Have hydrating, repairing and anti-wrinkle effects on the skin (patent EP 1 064 008).
- Said protein fraction of seeds can be characterized as "very polar".
- the seeds are composed of sterols (campesterol, stigmasterol, ⁇ -sitosterol, ⁇ 5-avenasterol, clerosterol ...), fatty acids (C18: 1-oleic-68 to 76%, C16: 0 6 to 7.8%, C18: 0 4 to 7.6%, C20: 0 2.8 to 4% and C22: 0 to 6.7%), proteins (26 to 32%), fibers, tocopherol ( ⁇ , ⁇ , ⁇ : respectively, 134, 93 and 48 mg / kg of oil).
- the seeds also contain glucosinolates including 4- ( ⁇ -L-rhamnopyranosyloxy) -benzylglucosinolate. It has also been described that the leaves and seeds of Moringa sp. contain cytokinins such as zeatin, dihydrozeatine and isopenthyladenine (US Patent 2006/0222682).
- the applicant has demonstrated the use of a specific extract of whole seeds of Moringa sp. comprising oil (including triglycerides, fatty acids and polar lipids) and polyphenols as active ingredient in cosmetic and / or dermatological compositions.
- oil including triglycerides, fatty acids and polar lipids
- polyphenols as active ingredient in cosmetic and / or dermatological compositions.
- the present invention thus relates to an extract of whole seeds of Moringa sp. containing oil (including triglycerides, fatty acids and polar lipids) and polyphenols.
- oil including triglycerides, fatty acids and polar lipids
- polyphenols including triglycerides, fatty acids and polar lipids
- whole seeds is intended to mean seeds which have not been freed of their integument.
- an oil content of 5% to 50% including (i) 2% to 10% of triglycerides and fatty acids and (ii) 5% to 15% of polar lipids; and a content of total polyphenols of 0.01% to 5% (expressed as g of pyrogallol per 100 g of solids).
- said extract has an oil content of 25% to 40% (% by weight relative to the weight of the dry extract).
- the species of Moringa is preferably Moringa oleifera or Moringa drouhardii.
- Said extract of Moringa sp. according to the present invention is obtained from whole seeds of Moringa sp., advantageously dried, crushed and then subjected to at least one extraction with a medium polar solvent.
- the term "medium polar solvent” is intended to mean a solvent chosen from the group consisting of a C 1 to C 4 alcohol, acetone, a water / alcohol mixture and an acetone / acetone mixture. water, used alone or in mixtures.
- this ethanol / water mixture will be characterized by various ethanol / water proportions of 9/1 to 7/3 (v / v).
- the medium polar solvent is an ethanol / water mixture of 9/1 or 3/1 (v / v).
- the extraction is carried out with stirring or in a static manner, at reflux or at ambient temperature, in a ratio plant weight / solvent volume that can vary from 1/5 to 1/20, for a period of 30 minutes to 48 hours.
- the extraction can be renewed 2 or 3 times.
- the marc is then separated from the extract by centrifugation or filtration and the solution may be more or less concentrated until a solids content is obtained with yields ranging from 5% to 10%.
- a support may be added during the drying step in proportions by weight relative to the dry matter extracted, which may vary from 1% to 75%.
- the support may be maltodextrin, lactose, silica or any other cosmetologically acceptable carrier and solubilizing the extract, such as, for example, the propylene glycol / oleic alcohol mixture ethoxylated in various proportions.
- the extract of Moringa sp. obtained is characterized by its oil content (including triglycerides, fatty acids and polar lipids) and polyphenols.
- Another subject of the present invention relates to such an extract of Moringa sp. for its use as an anti-aging active ingredient.
- said extract is intended to combat all the signs of skin aging in people with mature skin.
- the term "mature skin” is intended to mean the skin of persons who are typically over 55 years old and more preferably over 60 years old.
- the marks of aging of the skin result in particular in a loss of firmness and / or elasticity and / or tonicity and / or suppleness of the skin and the formation of wrinkles and fine lines.
- the object of the present invention is therefore to provide a new active capable of providing both protection, hydration and nutrition to the epidermis / mature skin, and consequently to give the skin smoothing effects. , anti-loosening, restructuring.
- the Applicant has evaluated the overall anti-aging action of extracts of Moringa sp. according to the present invention.
- the extract according to the present invention promotes hydration, smoothing, non-loosening, and restructuring of the skin.
- the extract according to the present invention thus makes it possible to embellish and unify the skin complexion.
- Another object of the present invention is the use of an extract as defined to enhance and restore the barrier function of the skin.
- the expression "reinforcing the barrier function of the skin” means improving the barrier function of the skin.
- One of the fundamental functions of the skin is to provide a barrier between the body and the external environment, opposing in a sense the penetration into the epidermis of fungi, bacteria and allergens of the environment ("outside-in” ) and in the other direction to the water loss (“inside-out”).
- the epidermis is a pluristratified epithelium, of ectodermal origin, in perpetual renewal.
- the basal layer There are several layers of different morphological and cellular composition, from the inside to the outside: the basal layer, a cell base whose keratinocytes have a very strong proliferation capacity which allows the self-renewal of the epidermis then the suprabasal layers (the granular, thorny layers) and finally the stratum corneum (Stratum Corneum, SC). These stages correspond to more and more advanced levels of keratinocyte differentiation.
- the keratinocytes of the basal layer lose their capacity for proliferation as soon as they enter a process of migration towards the surface of the epidermis, during which the keratinocytes will express a program of differentiation leading to the cornification, a process of programmed cell death.
- the cutaneous barrier function is ensured in the first place by the stratum corneum, a solid and tight assembly formed of two compartments: - a lipid-rich intercorneocyte cement: the lipids, organized in layers and covalently linked to the cells, limit the penetration of the molecules through the stratum corneum;
- cornified cells dead and devoid of organelles (corneocytes), which correspond to the final stage of the keratinocyte differentiation.
- the integrity of the extracellular lipid cement as well as all the cellular elements of the stratum corneum and the balance between keratinocyte proliferation and differentiation are essential for maintaining a functional epidermal barrier function.
- the disruption of the barrier function makes the body sensitive to external aggression and dehydration.
- the improvement of the barrier function is crucial when the barrier function of the skin is impaired and it is necessary to restore it. This is the case in a certain number of physiological states, in response to time (skin aging) or in connection with the hormonal context or stress. The speed of this restoration allowing the return to homeostasis is delayed.
- the cutaneous barrier function is impaired in the majority of the most common skin conditions in the population that are often accompanied by an inflammatory component (dry skin ).
- the improvement of the barrier function may also be advantageous when it is desired to consolidate the native function of the skin, in order to confer in particular on the body a better resistance to the external aggressions against which it is likely to be exposed, in particular Environmental type (Ultraviolet, humidity, outdoor temperature, pollution, burns).
- the barrier function of the skin includes all the mechanisms of natural defense against the aggressions to which it is subject. The essential element providing this function is located in the most superficial part of the epidermis, at the level of the stratum corneum, called the stratum corneum.
- the use of the extract according to the present invention is particularly effective for strengthening and restoring the cutaneous barrier function.
- Another subject of the present invention relates to a cosmetic and / or dermatological composition
- a cosmetic and / or dermatological composition comprising, as active ingredient, an extract of whole seeds of Moringa sp. according to the invention and at least one cosmetologically and / or dermatologically acceptable excipient.
- Said cosmetic and / or dermatological composition according to the present invention comprises a quantity of dry extract of whole seeds of Moringa sp. between 0.1 g and 5 g per 100 g of said composition.
- said amount of Moringa sp. is between 0.25 g and 1 g per 100 g of cosmetic and / or dermatological composition.
- the invention relates to an anti-aging cosmetic composition.
- said cosmetic composition is intended to combat all the signs of skin aging in people with mature skin.
- the anti-aging cosmetic composition according to the present invention may contain, in addition, one or more other active ingredients such as active agents for sunscreen and / or skin depigmenting active agents.
- the active ingredients for sun protection are furthermore chosen from among chemical synthesis molecules known for their anti-UVA action, for their anti-UVB action such as octocrylene and / or dioctyl butamido triazone and / or bis-ethylhexyloxyphenyl. methoxyphenyl triazine
- the active agents for depigmentation of the skin, to lighten and even out the complexion may be, in addition, niacinamide, vitamin C and its derivatives.
- the cosmetologically acceptable excipient for obtaining an anti-aging cosmetic composition is chosen to allow topical or oral administration.
- the topical form is chosen from the group consisting of a milk, a cream, a balm, an oil, a lotion, a gel, a foaming gel, a ointment, spray, etc.
- the oral form is chosen from the group consisting of tablets, capsules, lozenges, powder, granules, solutions or oral suspensions.
- the invention also relates to a cosmetic and / or dermatological composition intended to strengthen and restore the barrier function of the skin.
- the cosmetologically and / or dermato logically acceptable excipient for obtaining a cosmetic and / or dermatological composition reinforcing and restoring the barrier function of the skin is chosen to allow topical administration.
- the topical form is chosen from the group consisting of a milk, a cream, a balm, an oil, a lotion, a gel, a foaming gel, a ointment, spray, etc.
- Another subject of the present invention relates to a cosmetic process for combating all the signs of cutaneous aging in persons with mature skin, characterized in that it involves the use, topically or orally, of an extract of whole seeds of Moringa sp. according to the invention.
- Example 3 20 g of dried and ground Moringa drouhardii whole seeds are extracted with 200 ml of 90:10 ethanol / water at reflux for 1 hour. The extracted solution is recovered by solid / liquid separation and dried on a rotary evaporator at 50 ° C. 1.29 g of extract are thus obtained in the form of a yellow-brown paste titrating at 35% of oil (triglycerides fatty acids and polar lipids) and 1.3% of total polyphenols expressed as pyrogallol.
- oil triglycerides fatty acids and polar lipids
- Siloxane (cytclopenta) decamethyl 1 to 8 g Glycerine 99.5% 1 to 5 g
- the antioxidant activity of the Moringa oleifera seed extract according to the present invention was evaluated with the DPPH test. This test is based on the measurement of the antioxidant trapping capacity of the stable 2,2-diphenyl-1-picrylhydrazyl radical.
- Results The results obtained are expressed as IC50, corresponding to the concentration giving 50% reduction in the absorbance of a methanolic solution of DPPH at 0.06 mM.
- the extract according to the invention has an antioxidant activity mainly provided by the molecules present in the integument.
- Results 65 ⁇ g of extract according to Example 1 are necessary to obtain an activity equivalent to the activity detected for 1 ⁇ g of trolox: activity equivalent to lycopene, a molecule known for its antioxidant activity.
- the epidermis plays a major protective role in providing a chemical and mechanical barrier for the body. It ensures the maintenance of the seal, namely the skin barrier function. Corneocytes, keratinocytes of the stratum corneum, associated with a lipid matrix, largely ensure this function. Nevertheless the deeper layers intervene in the setting up of the actors of this function. The differentiation capacity of the keratinocytes of the epidermis will guarantee the establishment of a functional selective permeability barrier (Elias PM, J Invest Dermatol 125 183-200 (2005)).
- epidermal differentiation is mainly focused on the evolution of structural proteins that are keratins and that contribute to the architectural integrity of the epidermis. Their expression varies according to the degree of maturation of the keratinocytes.
- Basic keratin 1 and acidic keratin 1 are early markers of keratinocyte differentiation present in the basal layer of the epidermis.
- transglutaminases such as transglutaminase 1 (TG1) (Houben E, et al., Skin Pharmacol Physiol, 20 (3): 122-32 (2007)).
- keratinocyte lipids are at the origin of the intercorneocyte lipid cement essential for the cutaneous barrier, the formation of which represents the final phase of epidermal terminal differentiation.
- This extracellular lipid matrix provides the main barrier to transcutaneous movements of water and electrolytes Mizutani Y., et al. FEBS Lett. 563: 93 (2004))
- a number of enzymes and lipid transporters see their keratinocyte expression increase with differentiation.
- certain members of the ABC (Adenosine Triphosphate Binding Cassette transporter) family play a major role in the steps of lipid barrier implantation.
- ABC Gl which carries glycerol specifically
- ABC A12 essential for the transfer of lipid precursors in the lamellar bodies
- Epidermal ceramides play a major specific role and represent an essential marker of the level of functionality of the skin barrier.
- enzymes involved in the synthesis of cutaneous ceramides see their expression and their activity specifically increased during a rupture of the epidermal barrier function and with the level of epidermal differentiation. This is the case in particular of Sphingolipid C4-hydroxylase / delta-4 desaturase or hDES2 whose dihydroceramide hydroxylase activity contributes to the synthesis of cutaneous phytoceramides in humans (Feingold, KR J Lipid Res 48: 2531-2546 ( 2007)).
- results are expressed as a percentage of stimulation of the gene expression (mRNA) of different markers of epidermal differentiation expressed by NHKs (compared to untreated cells). A significant positive effect is considered from 100% stimulation.
- the results obtained are shown in the table below.
- Table 1 Effect of vitamin D3, roziglitazone and the extract according to the invention from a model of differentiated normal human keratinocytes (NHK).
- the extract prepared according to Example 1 at 20 ⁇ g / ml induces the gene expression of hDES2 and ABC Gl.
- the extract prepared according to Example 1 makes it possible to restore the lipidic epidermal differentiation at the origin of the establishment of the hydrophobic barrier making it possible to limit skin dehydration, which is particularly encountered in mature skin.
- the extract according to Example 1, at 1 and 10 ⁇ g / ml makes it possible to restore the expression of Kl (11 and 35% respectively) and involucrine (15% for 10 ⁇ g / ml).
- Extracellular matrix is a dynamic structure with a structural and regulatory role for tissues. It gives the skin its turgidity and its mechanical properties: firmness, elasticity and tone. At the level of the epidermis it occupies the intercellular space and plays a role of maintenance for the epidermal edifice. It also exchanges between cells of the epidermis and plays a role in cell activity.
- the ECM of the epidermis consists in particular of collagen (fibrous protein) type IV. When a cell is senescent, the components of the ECM are mainly degraded by enzymes of the zinc endopeptidase type called matrix metalloproteinases or MMPs.
- MMP-9 is a gelatinase that has activity against denatured collagen molecules (gelatin) but can also cleave native molecules of type IV, V and VII collagen.
- the extract prepared according to Example 1 inhibits the gene expression of MMP-9 at 1, 10 and 30 ⁇ g / ml, and this significantly at the three concentrations.
- the extract prepared according to Example 1 makes it possible to restore the mechanical properties of the MEK: firmness, elasticity and tone of the ECM of the skin and also makes it possible to restore the protein structure of the epidermis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080027814.4A CN102458355B (zh) | 2009-06-22 | 2010-06-17 | 辣木属的种的完整种子的提取物及其在化妆品和/或皮肤病学组合物中的用途 |
US13/377,943 US20120128607A1 (en) | 2009-06-22 | 2010-06-17 | Extract of whole seeds of morninga sp, and use thereof in cosmetic and/or dermatological compositions |
SG2011090768A SG176729A1 (en) | 2009-06-22 | 2010-06-17 | Extract of whole seeds of moringa sp., and use thereof in cosmetic and/or dermatological compositions |
MX2011012375A MX2011012375A (es) | 2009-06-22 | 2010-06-17 | Extracto de semillas enteras de moriga sp y uso del mismo en composiciones cosmeticas y/o dermatologicas. |
RU2012102012/15A RU2545708C2 (ru) | 2009-06-22 | 2010-06-17 | Экстракт цельных семян moringa sp. и его применение в косметических и/или дерматологических композициях |
MA34411A MA33400B1 (fr) | 2009-06-22 | 2010-06-17 | Extrait de graines entieres de moringa sp et son utilisation dans des compositions cosmetiques et/ou dermatologiques |
UAA201200599A UA108850C2 (uk) | 2009-06-22 | 2010-06-17 | Екстракт цілісного насіння видів moringa та його застосування у косметичній та/або дерматологічній композиції |
CA2765023A CA2765023A1 (fr) | 2009-06-22 | 2010-06-17 | Extrait de graines entieres de moringa sp. et son utilisation dans des compositions cosmetiques et/ou dermatologiques |
JP2012516818A JP5937965B2 (ja) | 2009-06-22 | 2010-06-17 | モリンガ種の完全な種子の抽出物並びに化粧品組成物及び/又は皮膚科学的組成物におけるその使用 |
EP10734255A EP2445480A2 (fr) | 2009-06-22 | 2010-06-17 | Extrait de graines entieres de moringa sp et son utilisation dans des compositions cosmetiques et/ou dermatologiques |
TNP2011000589A TN2011000589A1 (fr) | 2009-06-22 | 2011-11-18 | Extrait de graines entieres de moringa sp. et son utilisation dans des compositions cosmetiques et/ou dermatologiques |
HK12110120.8A HK1169325A1 (en) | 2009-06-22 | 2012-10-12 | Extract of whole seeds of moringa sp., and use thereof in cosmetic and or dermatological compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0954235A FR2946879B1 (fr) | 2009-06-22 | 2009-06-22 | Extrait de graines entieres de moringa sp. et son utilisation dans des compositions cosmetiques et/ou dermatologiques. |
FR0954235 | 2009-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010149895A2 true WO2010149895A2 (fr) | 2010-12-29 |
WO2010149895A3 WO2010149895A3 (fr) | 2011-12-22 |
Family
ID=41611362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2010/051207 WO2010149895A2 (fr) | 2009-06-22 | 2010-06-17 | Extrait de graines entieres de moringa sp et son utilisation dans des compositions cosmetiques et/ou dermatologiques |
Country Status (16)
Country | Link |
---|---|
US (1) | US20120128607A1 (fr) |
EP (1) | EP2445480A2 (fr) |
JP (1) | JP5937965B2 (fr) |
KR (1) | KR20120108916A (fr) |
CN (1) | CN102458355B (fr) |
CA (1) | CA2765023A1 (fr) |
FR (1) | FR2946879B1 (fr) |
GE (1) | GEP20156293B (fr) |
HK (1) | HK1169325A1 (fr) |
MA (1) | MA33400B1 (fr) |
MX (1) | MX2011012375A (fr) |
RU (1) | RU2545708C2 (fr) |
SG (1) | SG176729A1 (fr) |
TN (1) | TN2011000589A1 (fr) |
UA (1) | UA108850C2 (fr) |
WO (1) | WO2010149895A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012241186A (ja) * | 2011-05-20 | 2012-12-10 | Teruaki Kano | ワサビノキ科に属するモリンガの乾燥殺菌粉末及び液体抽出と酸化腐敗防止方法。 |
CN103155954A (zh) * | 2013-04-01 | 2013-06-19 | 张修本 | 一种杀虫剂 |
CN103223000A (zh) * | 2012-01-31 | 2013-07-31 | 株式会社爱茉莉太平洋 | 辣木种子提取物的皮肤外用剂组合物 |
KR20130122233A (ko) * | 2012-04-30 | 2013-11-07 | (주)아모레퍼시픽 | 레스베라트롤을 함유하는 화장료 조성물 |
CN104306432A (zh) * | 2014-10-31 | 2015-01-28 | 徐淳铣 | 一种用于洗浴护肤的天然药物制剂及其制备方法 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014053944A1 (fr) * | 2012-10-03 | 2014-04-10 | University Of The Witwatersrand, Johannesburg | Extrait de moringaceae et procédé pour préparer l'extrait |
KR101408837B1 (ko) * | 2012-12-31 | 2014-06-19 | 웅진식품주식회사 | 비타민과 모링가 잎 추출물을 포함하는 음료 조성물 및 그 제조 방법 |
KR20140143655A (ko) * | 2013-06-07 | 2014-12-17 | 한국원자력연구원 | 모링가 잎의 수용성 추출물을 유효성분으로 포함하는 암 치료 또는 예방용 조성물 및 모링가 잎의 추출물의 제조방법 |
FR3008315B1 (fr) * | 2013-07-11 | 2020-07-24 | Thorel Jean Noel | Composition topique cosmetique protectrice vis-a-vis des xenobiotiques |
CN104622753B (zh) * | 2015-02-10 | 2017-08-25 | 广东雅倩化妆品有限公司 | 一种天然洗护发剂及其制备方法和应用 |
CN104800121B (zh) * | 2015-04-16 | 2018-06-01 | 福建泉州盛和工艺品有限公司 | 一种含有软玉的日用品组合物及其制备方法和应用 |
CN104840398A (zh) * | 2015-05-18 | 2015-08-19 | 陈丽丹 | 一种天然辣木保健精油 |
CN104873554A (zh) * | 2015-05-28 | 2015-09-02 | 郑艳华 | 辣木籽及其提取物在作为促进学习记忆的药物、保健食品 |
CN105125449B (zh) * | 2015-09-24 | 2016-12-07 | 广州市索柔生物科技有限公司 | 一种抗污染化妆品组合物 |
JP6200122B1 (ja) * | 2015-10-28 | 2017-09-20 | 太陽化学株式会社 | モリンガエキス |
WO2017185227A1 (fr) * | 2016-04-26 | 2017-11-02 | L'oreal | Composition permettant le traitement de fibres de kératine |
FR3076460B1 (fr) | 2018-01-09 | 2020-11-13 | Basf Beauty Care Solutions France Sas | Utilisation cosmetique d'un extrait proteique des graines de moringa oleifera |
KR102151043B1 (ko) * | 2018-04-18 | 2020-09-02 | 제이준코스메틱 주식회사 | 초임계 추출법으로 제조된 모링가 시드 박(seed bark)을 함유하는 화장료 조성물 |
US20210353701A1 (en) * | 2018-11-02 | 2021-11-18 | Shiseido Company, Ltd. | Ultraviolet light-induced inflammation suppressing agent comprising alternative autophagy inducing agent |
FR3110419B1 (fr) | 2020-05-21 | 2023-07-14 | Agence Francaise Pour Le Dev D’Al Ula | Extrait de graines de Moringa peregrina riche en 2,5-diformylfuran, son procédé d’obtention et son utilisation dans des compositions cosmétiques |
US11717476B2 (en) * | 2020-05-21 | 2023-08-08 | Agence Franaise Pour Le Developpement D' Al Ula | Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining same and use thereof in cosmetic compositions |
FR3110345B1 (fr) | 2020-05-21 | 2024-03-29 | Agence Francaise Pour Le Dev D’Al Ula | Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques. |
US20230070929A1 (en) | 2020-05-21 | 2023-03-09 | Agence Francaise Pour Le Developpement D'al Ula | Extract of moringa peregrina seed cake, method for obtaining same and use thereof in cosmetic or nutricosmetic compositions |
FR3110346B1 (fr) | 2020-05-21 | 2023-07-14 | Agence Francaise Pour Le Dev D’Al Ula | Extrait du tourteau des graines de Moringa peregrina, son procédé d’obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques |
WO2024056586A2 (fr) * | 2022-09-16 | 2024-03-21 | Unilever Ip Holdings B.V. | Composition de nettoyage auto-moussante |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1064008A1 (fr) | 1998-03-24 | 2001-01-03 | Laboratoires Serobiologiques(Societe Anonyme) | Utilisation d'au moins un extrait proteique de graines de plantes du genre moringa et composition cosmetique et/ou pharmaceutique correspondante |
US20060222682A1 (en) | 2005-03-18 | 2006-10-05 | Andrews David A | Nutraceutical Moringa composition |
US20060275247A1 (en) | 2005-06-01 | 2006-12-07 | Revlon Consumer Products Corporation | Cosmetic Compositions With Moringa Seed Extract |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5142113B2 (ja) * | 1997-07-31 | 2013-02-13 | 三省製薬株式会社 | メラニン生成抑制剤およびその用途 |
US6858588B2 (en) * | 2003-03-31 | 2005-02-22 | Council Of Scientific And Industrial Research | Nitrile glycoside useful as a bioenhancer of drugs and nutrients, process of its isolation from moringa oleifera |
JP2005325091A (ja) * | 2004-05-12 | 2005-11-24 | Ikeda Corp | 外用剤組成物 |
JP4810078B2 (ja) * | 2004-08-23 | 2011-11-09 | 太田油脂株式会社 | 酸化安定性に優れたモリンガオイルとその製造方法 |
US7404975B2 (en) * | 2006-05-10 | 2008-07-29 | Academia Sinica | Moringa crude extracts and their derived fractions with antifungal activities |
KR20090046011A (ko) * | 2007-11-05 | 2009-05-11 | (주)더페이스샵코리아 | 화장료 조성물 |
-
2009
- 2009-06-22 FR FR0954235A patent/FR2946879B1/fr active Active
-
2010
- 2010-06-17 JP JP2012516818A patent/JP5937965B2/ja not_active Expired - Fee Related
- 2010-06-17 WO PCT/FR2010/051207 patent/WO2010149895A2/fr active Application Filing
- 2010-06-17 MX MX2011012375A patent/MX2011012375A/es not_active Application Discontinuation
- 2010-06-17 CA CA2765023A patent/CA2765023A1/fr not_active Abandoned
- 2010-06-17 KR KR1020117027874A patent/KR20120108916A/ko not_active Application Discontinuation
- 2010-06-17 SG SG2011090768A patent/SG176729A1/en unknown
- 2010-06-17 EP EP10734255A patent/EP2445480A2/fr not_active Withdrawn
- 2010-06-17 US US13/377,943 patent/US20120128607A1/en not_active Abandoned
- 2010-06-17 MA MA34411A patent/MA33400B1/fr unknown
- 2010-06-17 CN CN201080027814.4A patent/CN102458355B/zh not_active Expired - Fee Related
- 2010-06-17 RU RU2012102012/15A patent/RU2545708C2/ru not_active IP Right Cessation
- 2010-06-17 UA UAA201200599A patent/UA108850C2/uk unknown
- 2010-06-17 GE GEAP201012537A patent/GEP20156293B/en unknown
-
2011
- 2011-11-18 TN TNP2011000589A patent/TN2011000589A1/fr unknown
-
2012
- 2012-10-12 HK HK12110120.8A patent/HK1169325A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1064008A1 (fr) | 1998-03-24 | 2001-01-03 | Laboratoires Serobiologiques(Societe Anonyme) | Utilisation d'au moins un extrait proteique de graines de plantes du genre moringa et composition cosmetique et/ou pharmaceutique correspondante |
US6500470B1 (en) | 1998-03-24 | 2002-12-31 | Laboratoires Serobiologiques (Societe Anonyme) | Use of at least one protein extract of the moringa genus plant seeds and corresponding cosmetic and/or pharmacological composition |
US20060222682A1 (en) | 2005-03-18 | 2006-10-05 | Andrews David A | Nutraceutical Moringa composition |
US20060275247A1 (en) | 2005-06-01 | 2006-12-07 | Revlon Consumer Products Corporation | Cosmetic Compositions With Moringa Seed Extract |
Non-Patent Citations (7)
Title |
---|
ELIAS PM, J INVEST DERMATOL, vol. 125, 2005, pages 183 - 200 |
FEINGOLD, K.R., J LIPID RES, vol. 48, 2007, pages 2531 - 2546 |
HOUBEN E ET AL., SKIN PHARMACOL PHYSIOL., vol. 20, no. 3, 2007, pages 122 - 32 |
HUKKERI ET AL., INDIAN J. PHARM. SCI., vol. 68, 2006, pages 124 - 126 |
MIZUTANI Y. ET AL., FEBS LETT., vol. 563, 2004, pages 93 |
TAGAMI, ARCH. DERM. RES., 2007 |
THE INDIAN MATERIA MEDICA, pages 811 - 816 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012241186A (ja) * | 2011-05-20 | 2012-12-10 | Teruaki Kano | ワサビノキ科に属するモリンガの乾燥殺菌粉末及び液体抽出と酸化腐敗防止方法。 |
CN103223000A (zh) * | 2012-01-31 | 2013-07-31 | 株式会社爱茉莉太平洋 | 辣木种子提取物的皮肤外用剂组合物 |
KR20130122233A (ko) * | 2012-04-30 | 2013-11-07 | (주)아모레퍼시픽 | 레스베라트롤을 함유하는 화장료 조성물 |
KR101893970B1 (ko) * | 2012-04-30 | 2018-08-31 | (주)아모레퍼시픽 | 레스베라트롤을 함유하는 화장료 조성물 |
CN103155954A (zh) * | 2013-04-01 | 2013-06-19 | 张修本 | 一种杀虫剂 |
CN104306432A (zh) * | 2014-10-31 | 2015-01-28 | 徐淳铣 | 一种用于洗浴护肤的天然药物制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
TN2011000589A1 (fr) | 2013-05-24 |
FR2946879A1 (fr) | 2010-12-24 |
WO2010149895A3 (fr) | 2011-12-22 |
HK1169325A1 (en) | 2013-01-25 |
RU2012102012A (ru) | 2013-07-27 |
JP2012530769A (ja) | 2012-12-06 |
CN102458355B (zh) | 2015-03-04 |
KR20120108916A (ko) | 2012-10-05 |
FR2946879B1 (fr) | 2012-05-18 |
GEP20156293B (en) | 2015-06-10 |
CN102458355A (zh) | 2012-05-16 |
UA108850C2 (uk) | 2015-06-25 |
EP2445480A2 (fr) | 2012-05-02 |
MX2011012375A (es) | 2011-12-08 |
RU2545708C2 (ru) | 2015-04-10 |
SG176729A1 (en) | 2012-01-30 |
CA2765023A1 (fr) | 2010-12-29 |
JP5937965B2 (ja) | 2016-06-22 |
US20120128607A1 (en) | 2012-05-24 |
MA33400B1 (fr) | 2012-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010149895A2 (fr) | Extrait de graines entieres de moringa sp et son utilisation dans des compositions cosmetiques et/ou dermatologiques | |
FR3065172A1 (fr) | Preparation cosmetique contenant un extrait de truffe blanche et procede cosmetique associe | |
CA2258800A1 (fr) | Composition anti-oxydante et/ou anti-elastase a base d'huile de lupin | |
WO2012085226A1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
WO2021156104A1 (fr) | Procédé d'obtention d'un extrait aqueux de lavande, compositions comprenant un tel extrait et leurs utilisations cosmétiques | |
FR2948023A1 (fr) | Compositions cosmetiques a base d'huile essentielle de rose pour la prevention des effets du vieillissement cellulaire au niveau dermique | |
KR102099783B1 (ko) | 행운목과 토끼풀의 혼합 추출물을 유효성분으로 함유하는 피부 화장료 조성물 | |
WO2016162343A1 (fr) | Extrait hydro-alcoolique de schinus molle, compositions cosmetiques le comprenant et leurs utilisations cosmetiques | |
EP0809484B1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de bertholletia | |
KR102476670B1 (ko) | 혼합 추출물을 포함하는 화장료 조성물 | |
EP0831865A1 (fr) | Composition capillaire comprenant un extrait de myrte, son procede de preparation et son utilisation notamment pour un traitement antipelliculaire | |
KR102646545B1 (ko) | 비비추 추출물을 포함하는 피부 미백 또는 피부장벽 개선용 화장료 조성물 | |
WO2022043641A1 (fr) | Huile de silybum marianum (l.) gaertn. dans le renforcement de la fonction barrière de la peau | |
KR20190048935A (ko) | 적양파추출물을 흑효모 균사체로 발효한 적양파 흑효모 발효액을 유효성분으로 함유하는 화장료 조성물 | |
FR3048882A1 (fr) | Extraits de coque de noix de coco, compositions l'incluant et utilisations | |
WO2018178604A1 (fr) | Compositions cosmétiques comprenant une association d'ingrédients et leurs utilisations | |
FR3052979A1 (fr) | Composition cosmetique biomimetique comprenant une association d’huile d’argan et d’extraits hydroglycerine d’algues brunes, d’alaria esculenta et de myrte | |
FR3059549B1 (fr) | Utilisation cosmetique d’un extrait d’ulex europaeus. | |
WO2022084638A1 (fr) | Huile de paeonia x suffruticosa andrews pour la protection de la peau et des cheveux | |
WO2024089188A1 (fr) | Ingredient actif cosmetique issu d'une fraction non volatile d'exsudat de canarium et ses utilisations | |
WO2023152080A1 (fr) | Procede d'obtention d'extraits vegetaux comprenant une etape d'autofermentation, compositions comprenant de tels extraits et leurs utilisations cosmetiques | |
FR2968214A1 (fr) | Nouvelles compositions anti-age | |
FR3115460A1 (fr) | UTILISATION D’UN EXTRAIT DE LILAS DES INDES DANS DES COMPOSITIONs COSMETIQUES ANTI-ÂGE | |
OA21068A (fr) | Extrait du tourteau des graines de Moringa Peregrina, son procédé d'obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques. | |
FR3110346A1 (fr) | Extrait du tourteau des graines de Moringa peregrina, son procédé d’obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080027814.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10734255 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/012375 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20117027874 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2765023 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010734255 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012516818 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12537 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012102012 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13377943 Country of ref document: US |